Endo International plc (EO7.F)
- Previous Close
0.0100 - Open
0.0100 - Bid --
- Ask --
- Day's Range
0.0100 - 0.0100 - 52 Week Range
0.0002 - 0.1390 - Volume
3,000 - Avg. Volume
6,658 - Market Cap (intraday)
2.352M - Beta (5Y Monthly) 0.80
- PE Ratio (TTM)
-- - EPS (TTM)
-9.7000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.57
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company offers branded pharmaceuticals, including XIAFLEX to treat adult patients with Dupuytren's contracture and Peyronie's disease; SUPPRELIN LA to treat central precocious puberty in children; AVEED to treat hypogonadism; NASCOBAL nasal spray to treat vitamin B12 deficiency; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET for pain management; TESTOPEL, an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; and EDEX to treat erectile dysfunction, as well as opioid products to treat pain associated with post-herpetic neuralgia. It also provides ADRENALIN, a non-selective adrenergic agonist to treat anaphylaxis; VASOSTRICT, a vasopressin IV solution; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products. In addition, the company offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. Further, it provides specialty pharmaceutical products and over-the-counter products. The company sells its products to specialty physicians, wholesale distributors, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
www.endo.com2,931
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: EO7.F
Performance Overview: EO7.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EO7.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EO7.F
Valuation Measures
Market Cap
131.56k
Enterprise Value
-720.28M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.00
Price/Book (mrq)
--
Enterprise Value/Revenue
-0.36
Enterprise Value/EBITDA
0.35
Financial Highlights
Profitability and Income Statement
Profit Margin
-121.79%
Return on Assets (ttm)
4.43%
Return on Equity (ttm)
--
Revenue (ttm)
2.01B
Net Income Avi to Common (ttm)
-2.45B
Diluted EPS (ttm)
-9.7000
Balance Sheet and Cash Flow
Total Cash (mrq)
777.92M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
482.64M
Research Analysis: EO7.F
Company Insights: EO7.F
EO7.F does not have Company Insights